CompletedEUCTR 2005-004167-27
A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolarity type I to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo p...
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
- Listed locations
- Germany · Italy and 2 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 512
- Sponsor
- Pfizer, S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany, Italy, Spain, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-004167-27
- Official title
Show the full official title
A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo p...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Germany · Italy · Spain
1 more locations
- Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer, S.A.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...